The update to EU GMP Annex 1 offers market opportunities in aseptic operations, focusing on compliance with new standards. Key areas include contamination control, cleanroom design, and advanced ...
3d
VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...
VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...
The pharmaceutical and biotech industry is continuing to publish Sustainability Reports. That is because, given the nature of ...
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...
Parabilis Medicines CEO Mathai Mammen, M.D., Ph.D., told Fierce the industry had been in “retreat mode for some time” before its latest rebound. (mesh cube/iStock/Getty Images Plus) Elon Musk's SpaceX ...
In its annual Biotech Beyond Borders report, EY projects growth to continue throughout 2026, fueled primarily by the increased volume and value of M&A and licensing deals. (Techa Tungateja/GettyImages ...
The public biotech universe has shrunk by more than 20% since 2021, yet financial stress remains entrenched across the sector, according to a report from EY Tuesday. Hundreds of public biotech ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The transactions include upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results